Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

March 2, 2018: By Jon Swedien

Aerie Pharmaceuticals anticipates it will launch Rhopressa in the middle of Q2-2018, the company announced Feb. 28.

Aerie forecasts the open-angle glaucoma and ocular hypertension treatment will net between $20 million and $30 million in 2018, the company said. Rhopressa gained US FDA approval in December 2017.

The company said it expects to gain preferred formulary coverage for the majority of commercial payers for Rhopressa by late 2018, with most of the Medicare Part D coverage expected to start in 2019.

Aerie said it has commercial product and sample inventory currently on hand to cover more than a full year of expected demand. The company also plans to have its sales force of 100 territory managers in place and fully trained in time for the launch, said Vicente Anido Jr., PhD, Aerie’s chairman and CEO.

Aerie forecasts its cash burn for 2018 will range between $200 million to $210 million. That includes adjusted total operating expenses in the range of $155 million to $160 million, and capital and inventory build expenditures in the range of $45 million to $50 million, the company said.

Aerie had approximately $250 million in cash, cash equivalents, and investments as of Dec. 31, 2017, the company said.

In January, Aerie raised approximately $136 million in equity offering net proceeds from the issuance of 2.3 million shares, the company reported.

Rhopressa (netarsudil ophthalmic solution) 0.02% is a rho-associated protein kinase (rho kinase, or ROCK) inhibitor, a new class of medications proposed to lower intraocular pressure (IOP) by directly increasing trabecular outflow. The eye drop is administered once a day.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023